Baxter International Inc. (BAX) Stock Price & How to Invest

Baxter International makes essential hospital and critical-care products, including IV solutions, infusion pumps (the Novum IQ and legacy platforms), premixed and injectable drugs, surgical sealants, and connected-care hardware from the Hillrom acquisition. After decades as a sprawling healthcare conglomerate, Baxter reshaped itself: it spun off and then sold its Kidney Care segment (rebranded Vantive) to Carlyle for roughly $3.8 billion, using proceeds to reduce debt. What remains is a company centered on Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals, serving hospitals worldwide with high-volume, mission-critical supplies.

The investment picture is a turnaround, not a growth story. Q1 2026 sales from continuing operations were about $2.7 billion (up roughly 3% reported, down about 1% organic), adjusted EPS beat expectations at $0.36, but GAAP results showed a small loss and adjusted operating margin compressed sharply on special charges, a Novum IQ pump shipment hold, supply constraints, and inflation. New CEO Andrew Hider, who joined in late 2025 with a lean-manufacturing reputation, is focused on stabilizing execution and improving margins while the company works to bring leverage down. The stock trades at a modest multiple relative to peers, reflecting both the balance-sheet overhang and skepticism about how quickly the turnaround delivers.

The Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. Elevated debt (around $8.6 billion long-term) constrains flexibility and makes the company sensitive to interest costs. Margins have been hit by special charges, injectable supply constraints, inflation, recall- and hurricane-related items, and tariff exposure. Competition from Becton Dickinson, ICU Medical, B. Braun, and Fresenius Kabi is intense across infusion and IV products. The turnaround is early and could take longer than management projects.

11 analysts publish price targets on BAX, averaging $28.73 against a $25.48 price as of September 2026, or +12.8%. The published targets run from $23.00 to $40.00, a moderate spread, and the ratings split 2 buy, 11 hold, 0 sell. Over the last six months there have been 10 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full BAX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Baxter International Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Margin and operational turnaround. New CEO Andrew Hider brings a lean-manufacturing and continuous-improvement playbook aimed at reversing the sharp operating-margin compression seen recently. The most optimistic published target, $40.00, assumes this works close to its best case.

The case against. The Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. The most pessimistic target, $23.00, is roughly what BAX is worth if this bites instead.

Read the full bull and bear case on BAX, including what would have to change to break either one. Walnut is not an investment adviser.

No. Baxter International Inc. (BAX) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Baxter International Inc.'s investor relations page or your broker.

• Revenue (TTM, continuing ops): ~$10.7B
• Q1 2026 sales: ~$2.7B
• Q1 2026 adjusted EPS: ~$0.36
• Market cap: ~$11.5B
• Long-term debt: ~$8.6B
• Dividend (quarterly): ~$0.01 (cut Jan 2026)

Baxter trades at a modest valuation (price-to-sales near 1x) that reflects both its low-growth profile and the balance-sheet overhang. Full-year 2026 guidance calls for roughly flat to 1% sales growth on a GAAP basis. Reported profitability has been distorted by special charges, so adjusted metrics tell a more stable story than headline GAAP figures.

Other names that sit close to BAX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get BAX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so BAX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where BAX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

BAX is a transformation-stage medtech supplier whose story hinges on execution, margin recovery, and deleveraging rather than fast growth.

Whether BAX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is BAX a buy or a sell?, and where the stock could go from here in the BAX stock forecast.

For income investors, whether BAX pays a dividend and how the payout looks is covered in does BAX pay a dividend? And to weigh BAX against a peer, read the full side-by-side comparisons: BAX vs ICUI and BAX vs PFE.